NantKwest Launches First-in-class, First-in-human Phase I Clinical Trial With a Targeted PD-L1 t-haNK Cell Therapy in Patients With Solid Tumors

Stock Information for NantKwest Inc.

Loading

Please wait while we load your information from QuoteMedia.